Oncolys Biopharma Inc.’s lead compound Telomelysin (suratadenoturev, OBP-301) met the primary endpoint of exceeding the predefined threshold of local complete response, confirming clinical benefit in a phase II study in locally advanced esophageal cancer combined with radiation.
Korean bioventure GI Innovation Inc. inched closer to achieving its goal of “five tech transfer deals in five years” with another licensing deal for its allergy drug, GI-301, with Japan-based Maruho Co. Ltd. for ₩298 billion (US$220.7 million), although share prices still dropped on the news.
Korean bioventure GI Innovation Inc. inched closer to achieving its goal of “five tech transfer deals in five years” with another licensing deal for its allergy drug, GI-301, with Japan-based Maruho Co. Ltd. for ₩298 billion (US$220.7 million), although share prices still dropped on the news.
Drug discovery in Japan has been steadily declining, and it has reached a crisis point where swift action is needed or pharma companies will leave Japan or stop listing products here, said speakers at the BioJapan 2023 meeting held Oct. 10 to 13 in Yokohama, Japan.
Insanity has often been defined as doing the same thing and expecting different results, and Japan seems to be trapped in that rut largely because it can’t seem to do innovation differently, said speakers at the BioJapan 2023 meeting held Oct. 11 in Yokohama, Japan.
Japan’s economy has remained stagnant for the last few decades, and Prime Minister Fumio Kishida has heralded the biotech industry as a strategic industry to attract global partners, which was also one of the expectations for the BioJapan 2023 conference held Oct. 10-12 in Yokohama, drawing attendees from more than 37 countries and was the first live biotech industry event that welcomed foreigners since the COVID-19 pandemic.
Drug discovery in Japan has been steadily declining, and it has reached a crisis point where swift action is needed or pharma companies will leave Japan or stop listing products here, said speakers at the BioJapan 2023 meeting held Oct. 10 to 13 in Yokohama, Japan.
Japan’s economy has remained stagnant for the last few decades, and Prime Minister Fumio Kishida has heralded the biotech industry as a strategic industry to attract global partners, which was also one of the expectations for the BioJapan 2023 conference held Oct. 10-12 in Yokohama, drawing attendees from more than 37 countries and was the first live biotech industry event that welcomed foreigners since the COVID-19 pandemic.
Insanity has often been defined as doing the same thing and expecting different results, and Japan seems to be trapped in that rut largely because it can’t seem to do innovation differently, said speakers at the BioJapan 2023 meeting held Oct. 11 in Yokohama, Japan.
As pricing negotiations for Biogen Inc./Eisai Co. Ltd.’s newly approved Leqembi (lecanemab) for Alzheimer’s disease get underway at Japan’s Central Social Insurance Medical Council (Chuikyo), industry watchers see opportunity for potential drug price reform.
RSS
